AbbVie (ABBV) Payables (2012 - 2026)

AbbVie (ABBV) has 15 years of Payables data on file, last reported at $33.8 billion in Q1 2026.

• Payables for Q1 2026 came in at $33.8 billion, up 3.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.8 billion (up 3.49% YoY), and the FY2025 annual result was $37.2 billion, up 16.55% from the prior year.
• Payables eased to $33.8 billion in Q1 2026 per ABBV's latest filing, from $37.2 billion in the prior quarter.
• Over five years, Payables peaked at $37.4 billion in Q3 2025 and troughed at $22.6 billion in Q2 2022.
• A 5-year average of $29.7 billion and a median of $30.5 billion in 2024 frame the typical range for Payables.
• On a YoY basis, Payables climbed as much as 26.38% in 2024 and fell as far as 2.81% in 2024.
• A 5-year view of Payables shows it stood at $25.4 billion in 2022, then increased by 20.66% to $30.6 billion in 2023, then increased by 4.23% to $31.9 billion in 2024, then increased by 16.55% to $37.2 billion in 2025, then retreated by 9.29% to $33.8 billion in 2026.
• Business Quant data shows ABBV's Payables at $33.8 billion in Q1 2026, $37.2 billion in Q4 2025, and $37.4 billion in Q3 2025.